Pharmafile Logo
Pharmafocus logo
Advanced Search
exelixis_hq_web

Exelixis’ Cabometyx smashes Pfizer cancer drug in Phase II trial

October 11, 2016
Manufacturing and Production, Research and Development Cabometyx, Exelixis, Pfizer, Phase II, Sutent, advanced renal cell carcinoma

Phase II results presented by genomics-based discovery company  Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …

News
nordicnanovector_final_logo

Nordic Nanovector and LegoChem Biosciences enter into collaboration

October 11, 2016
Manufacturing and Production

The Norwegian company Nordic Nanovector and the South Korean company LegoChem Biosciences have begun a collaboration to develop novel CD37-targeting …

News
takeda_world

Takeda enters $790m cancer development deal

October 11, 2016
Manufacturing and Production, Research and Development Cancer, Crescendo Biologics, Takeda, clinical partnership, humabody

Takeda and Crescendo Biologics have shaken hands on a $790 million deal to develop and commercialise cancer therapeutics using Crescendo’s …

News

Roche granted further good news by FDA

October 11, 2016
Manufacturing and Production Actembra, Alecensa, FDA, Lucentis, Roche, United States, america

Roche was given further good news by FDA after receiving a Priority Review for its Lucentis drug – this news …

News
teva-kim-innes-250

New UK & Ireland general manager for Teva

October 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva, appointment

Kim Innes has been appointed by Teva as its new general manager of UK & Ireland. Innes succeeds Richard Daniell, …

Appointment
flag_of_the_united_arab_emirates

UAE’s pharmaceutical market projected to grow from $3 billion to $5.7 billion by 2020

October 10, 2016
Manufacturing and Production Abu Dhabi, Dubai, GlobalData, United Arab Emires, growth, medical tourism, pharmaceutical market

United Arab Emirates’ pharmaceutical market is set for growth of 13% annually to reach $5.7 billion by 2020, up from …

News
shutterstock_142740349_resize_3

Educating pharma

October 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing educated, funding, medical education, transparency

Originally published in the October issue of Pharmafocus, Sean Murray takes a look at how pharma continues to occupy a key …

Feature
opdivo_1_1

Failure for BMS’ Opdivo in lung cancer trial

October 10, 2016
Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq

Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …

News
roche__tree

Roche’s lung cancer success spells competition for BMS’ Opdivo

October 10, 2016
Research and Development, Sales and Marketing BMS, Roche, lung cancer, opdivo, tecentriq

Roche’s immune-system booster drug Tecentriq (atezolizumab) may cause trouble in the lung cancer field for leader Bristol-Myers Squibb’s Opdivo according …

News
msd_merck_night_building

MSD’s Keytruda twice as successful against standard therapy for lung cancer

October 10, 2016
Sales and Marketing Bristol-Myers Squibb, MSD, Merck, keytruda

MSD, known as Merck in North America, released data that displayed the success of their drug, Keytruda, in a 123-patient …

News
1280px-epi-pen_1

Mylan agrees $465m settlement over EpiPen misclassification

October 10, 2016
Business Services, Medical Communications, Sales and Marketing Heather Bresch, Mylan, Price hike, epipen

In the latest scandal in the EpiPen price hike saga, the US Department of Justice has made claims that the …

News
novartis_building

Novartis’ new drug muscles in on Pfizer’s territory

October 10, 2016
Sales and Marketing Eli Lilly, Novartis, Pfizer, ibrance, ribociclib

A drug developed by Novartis, ribociclib, when combined with an older drug, letrozole, has been shown to reduce risk of progression …

News

Woodley Equipment Company Limited Appoints Declan Boyle

October 7, 2016
clinical research, clinical trials

 

Appointment

NICE recommends Forxiga in Triple Therapy for Diabetes

October 7, 2016
Medical Communications AstraZeneca, Forxiga, NHS, NICE, diabetes, type 2 diabetes

The news of NICE’s approval of the Forxiga comes in a busy week for AstraZeneca. They have sold three drugs, …

News
gsk_china_2_2_0_1

Cancer Research UK receives ‘success payment’ from GlaxoSmithKline

October 7, 2016
Medical Communications GSK, GlaxoSmithKline, University of Manchester, cancer research

CRT and the University of Manchester were rewarded financially for their collaboration developing molecules targeting cancer epigenetics. The agreement between …

News
top_ten_stories

Top Ten articles in the Pharma Industry this week

October 7, 2016
Medical Communications

The beginning of October has seen the failure of big drugs in clinical trials have a big knock-on effect for …

News
astrazeneca_building_white

AstraZeneca sells off third drug in five days

October 7, 2016
Medical Communications AstraZeneca, Cilag GmbH, Johnson & Johnson, Rhinocort Aqua

AstraZeneca have completed a third sell off in the course of one week by divesting rights to Rhinocort Aqua outside …

News

ICU Medical to acquire Pfizer’s global infusion therapy business in $1 billion deal

October 6, 2016
Medical Communications Hospira, ICU medical, Pfizer, acquisition, infusion

The $1 billion deal that will take place as ICU Medical Inc. take over Pfizer’s Hospira Infusion Systems will be …

News

“Incorrect classification” of EpiPen leads to $1 billion bill for US government

October 6, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cost, Heather Bresch, Misclassification, Mylan, Price hike, classification, epipen, price, scandal

Mylan’s EpiPen woes show no sign of abating after CMS (Centers for Medicare and Medicaid Services) released figures that show …

News
sicorbio

Teva to sell Allergan’s UK & Ireland generics business for $770m

October 6, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva

Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.

News
The Gateway to Local Adoption Series

Latest content

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026

Incyclix Bio announces new additions to the Board

April 22, 2026

Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO

April 21, 2026